Pharmaceutical manufacturer Aesica has opened a new high capacity manufacturing facility following a £30 million investment at its Queenborough, Kent site.
The 10,000 sq m expansion is purpose-built for the production of a solid dose medication used in treating Type 2 diabetes, one of the world’s most common lifestyle diseases. Commercial production at the facility will start in November. Private equity investor Silverfleet Capital bought a stake in the pharma company in September 2011. This development…
This content is for subscribers only. Subscribe now for free to read the full article.
Already a subscriber? Login
